Early cancer drug study for adults with advanced tumors
Treatments studied
Part of Cancer, Skin clinical trials.
This Phase 1 study tests early (first-in-program) cancer medicines in people whose cancer has not been adequately controlled. It helps researchers learn the safest dose and early signs of whether the treatment may work for different tumor types and treatments.
Summary written for real people, not researchers, by Clin2.
Who can take part
- Be 18 years or older and be willing to sign consent before any study tests
- Be able to do study visits and procedures and follow the treatment and lab schedule
- Have an overall activity level that’s fairly good (ECOG 0 to 2)
- Have blood tests showing enough white blood cells, platelets, and hemoglobin within 30 days of starting treatment
- Have enough kidney and liver function based on recent lab results, and have an expected lifespan over 12 weeks
- If you can become pregnant, have a negative pregnancy test; also agree to use effective birth control during treatment
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study tests personalized, changing treatment plans (given before surgery) to find better options for your specific breast tumor. You may be asked for extra breast-tissue testing to help match you with the most suitable study drug(s).
This Phase 2 study tests a “precision platform” approach—treatment before surgery—based on specific test results from your breast tumor. It may help determine whether the treatment plan works better for people with particular breast cancer subtypes and healthy organ function.
This study tests how well and how safely different combinations of cancer drugs work for people with metastatic or inoperable locally advanced breast cancer. It may help by finding a better treatment option and collecting information to guide future care.
This trial helps match people with advanced, hard-to-treat cancers to targeted cancer drugs based on lab testing of their tumor. It may help if standard treatment isn’t working or isn’t available, and if your tumor has a “targetable” genetic change.
This trial tests the safety of combining two drugs, CX-5461 (Pidnarulex) and Trastuzumab Deruxtecan (T-DXd), in people with HER2-positive solid tumors or certain types of breast cancer. If you have advanced cancer that hasn't responded to other treatments, this study may be an option.
This trial tests a combination of two targeted therapies, Trastuzumab Deruxtecan (T-DXd) and Cetuximab, for people with colorectal cancer that has spread or cannot be removed by surgery. It is for those whose tumors have low levels of a protein called HER2 and who have already tried certain standard treatments.
Hear when a new HER2-positive Breast Cancer trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.